April 6, 2022 5:06pm

It will be a race to safe havens as risks shake not stir the cell and gene therapy sector share pricings

Pre-open indications: 1 Pimp/Pump and Promote - usual suspect Biostage (BSTG -$0.05)

What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?


If I have learned one thing as a former research analyst, venture and public fund investor now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed DOWN -144.67 points (-0.42%); the S&P closed DOWN -43.97 points (-0.97%) while the Nasdaq closed DOWN -315.35 points (-2.82%)

 

Henry’omics:

Indexes fell for a second day on Wednesday and rates soared to new heights as the Fed gave more guidance on how fast it will tighten monetary policy to fight inflation, raising concerns it may slow the economy.

  • The Fed’s release of its meeting minutes indicated on Wednesday afternoon that officials “generally agreed” it should shrink its balance sheet by $95 billion per month. The minutes also showed the central bank was considering larger rate hikes than its usual 25-basis-point, or quarter-point, increments.

Indexes “didn't like comments” from Fed Governor Lael Brainard (Tuesday), who said the Fed will "continue tightening monetary policy methodically through a series of interest rate increases and by starting to reduce the balance sheet at a rapid pace as soon as our May meeting." <IBD>

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened …

  • Wednesday opened negative at 5 up/30 downs, stayed negative at the mid-day at 9/26, ending with a negative close of 8/26 and 1 flat;

 

52-week low:

  • AVROBIO (AVRO) at $1.24

 

Pre-open Indications: 1 Pimp/Pump/Promote: <Biostage (BSTG) closed down -$0.05 with 1,527 shares traded after Tuesday’s +$0.59 with 8,743 shares traded, Monday’s +$0.49 with 8,809 shares traded, Friday’s $0.00 with 10 shares traded, Thursday’s -$0.10 with 124 shares traded, and last Wednesday’s +$0.50 with 3,926 shares traded>     

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628  … added with 35 to date <some dropped and others added>

 

Key Metrics:

  • Wednesday - Sector volume was LOW with 3 of the 8-upside having higher than the 3-month average volume with LOW volume of 7 of 26-downside having higher than the 3-month average volume;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB was down -0.15% and the XBI was up +0.19%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was up +1.07 points or +5.09% at 22.10

 

Jumping with share pricing momentum (8 of 8):

  • MiMedx (MDXG +$0.02),
  • Sangamo Therapeutics (SGMO +$0.06),
  • Verastem (VSTM +$0,07),
  • Chinook Therapeutics (KDNY +$0.59 after Tuesday’s -$1.90 and Monday’s +$0.57),
  • Fate Therapeutics (FATE +$0.65 after Tuesday’s -$2.31 and Monday’s +$1.07),
  • Ultragenyx (RARE +$2.15 after Tuesday’s +$2.55 and Monday’s +$0.78),
  • Agenus (AGEN +$0.01),

Hammered in today’s market (10 of 26):

  • Intellia Therapeutics (NTLA -$2.61 after Tuesday’s -$6.05),
  • Beam Therapeutics (BEAM -$1.65 after Tuesday’s -$5.90 and Monday’s +$2.41),
  • Alnylam Pharmaceuticals (ALNY -$1.44 after -Tuesday’s $1.86 after Monday’s -$7.52),
  • CRISPR Therapeutics (CRSP -$1.36 after Tuesday’s -$2.03 and Monday’s +$3.36),
  • BioLife Solutions (BLFS -$0.84 after Tuesday’s -$1.40 and Monday’s +$0.58),
  • Regenxbio (RGNX -$0.59 after Tuesday’s -$0.67),
  • Editas Medicine (EDIT -$0.58 after Tuesday’s -$1.02 and Monday’s +$1.13),
  • Global Blood Therapeutics (GBT -$0.52 after Tuesday’s +$0.09 and Monday’s +$1.39),
  • Caribou Biosciences (CRBU -$0.45),

AxoGen (AXGN -$0.41),

Flat:

  • Applied Genetic Technologies (AGTC)

 

April, Q2/2022:

  • Wednesday closed negative with 8 incliners, 26 decliners and 1 flat
  • Tuesday closed negative with 8 incliners, 26 decliners and 1 flat
  • Monday closed positive with 31 incliners and 4 decliners

 

The BOTTOM LINE:  As I stated on Monday, “On what (?) does this sector stay up as it can be a fickle place, as we’ve seen this year. Oversold/ Overbought – they bunch and then alternate … Are we entering a set-up for a selling opportunity?

Tuesday, “the Nasdaq, which never reclaimed its 200-day line, gapped down below its 21-day line on Wednesday and traded near session lows.”

And we were … again as the riskiest assets get hammered while indexes get whacked.

I stick to my view of anticipating the risks – as my careers focus has been “warning analysis”; risk to growth now takes center stage for how long separation of sentiment lasts and how deep the oversold dive.

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.